Topic and Country Assignments

Slides:



Advertisements
Similar presentations
Judging Web Validity Can you trust this site? Adapted from Dr. Ramesh Mehay Course Organiser, Bradford.
Advertisements

Understanding patents & medicine access the WTO, free trade agreements & patent law.
Actions Developing in Countries Accessing the WTO System Vung Tau, February 2006 “US – Brazil Compulsory licensing.
The Global Access to Medicines Movement Peter Maybarduk April 15, 2011.
Pharmaceuticals and Global Health: Successes, Challenges and Outlook 19. July 2013, University of Sussex Thomas B. Cueni, Secretary General Interpharma.
Benjamin Blasco Anna Ferretti Sophie Venet BIO615 Fall 2009.
XIX International AIDS Conference July 2012 Washington DC, USA The Brazilian experience: the campaign for access to lopinavir/ritonavir and efavirenz compulsory.
1 Review of Art 39.3 TRIPS – interpretation and controversy Sanya Smith Third World Network 25 August 2006 Bangkok.
Possible Impact of Market Exclusivity Extension on Pharmaceuticals in Thailand Chutima Akaleephan International Health Policy Program, Thailand 27 August.
Health Professional Students AIDS Advocacy Network Treat the People: Access to Essential AIDS Medications A Primer for Health Professional Students.
Medicine Access: Claims & Data Sanjay Basu. The Framework for Access The pipeline fallacy Patents and pricing.
A revised framework for global medicine access Sanjay Basu Reblaw X.
Intellectual Property
1 Licensing Agreements and the Protection of Intellectual Property Chapter 17 © 2005 Thomson/West Legal Studies In Business.
More on Generic Drugs Global Classrooms 2013 Rachel Hunkler.
IP News 指導老師:李柏靜 學生:黃馨葦 M /3/26.  Citing the high cost of one of the pharmaceutical industry's expensive new cancer drugs, India's patent.
1 FDA Thailand By HIV Module/Marketing Group Mr. Manaswee Arayasiri.
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
A very short introduction to patents & access to medicines.
The Role of TNCs and AIDS drugs – “Lives before profits”? L.O.s 1.To define the terms: TNC, Generic, “Big Pharma”, ARVs, HAART, Tiered Pricing. 2.To describe.
TRIPS flexibilities and examples which resulted in reduced medicine prices: Model legislation and compulsory licensing in Brazil Juliana V. Borges Vallini.
Subsequent Entry Biologics (SEBs) – Canada Presentation to AIPLA Biotechnology Committee January 25, 2012 Daphne C. Lainson
Why is protecting pharmaceutical patents a controversial issue in DCs? Poor DCs can neither produce nor afford to buy patented drugs. They need generic.
Procurement of patented and other essential medicines: challenges and opportunities Wilbert Bannenberg, MD MPH Zambia TRIPS workshop.
TRIPS, Doha and Access to Medicines: Recent Lessons CARSTEN FINK Globalization, Intellectual Property Rights and Social Equity: Challenges and Opportunities.
PATENTS AND HEALTH. A CASE STUDY OF THE UGANDAN CONTEXT. (PHA3 JULY 7 TH 2012 –CAPE TOWN, SOUTH AFRICA) MS. MARIAM AKIROR LLB (HONS) / DIP. SW / CPC. PROG.
Restrictions on exports of medicine: irrational public policy, backdoor efforts to marginalize compulsory licensing, or Northern protectionism? James Love.
 .
Pricing and the Pharmaceutical Industry What’s Realistic? What’s Smart? What’s Right?
Culture Change and the Modern World. Making the Modern World As world population grows and travel and communication get faster, You can find can of soda,
Patents, access to medicines and the WTO ’ s TRIPs Agreement Consultative meeting on incorporation of TRIPs Flexibilities Morogoro, Tanzania 24 July 2006.
Data Exclusivity and Access to Medicines – Empirical Evidence Hearing European Parliament: EU-India Free Trade Agreement: What Future for Patients in Developing.
Incentives for Innovation (Push and Pull) Andrew Alexandra Director Australian Research Council Special Research Centre for Applied Philosophy and Public.
Do Patents Make HIV/AIDS Medication Inaccessible to Patients in Sub-Saharan Africa? Abstract There has been debate surrounding the issue of patents and.
© 2008 International Intellectual Property June 24, 2009 Class 8 Patents: Multilateral Agreements (WTO TRIPS); Global Problem of Patent Protection for.
Title Page A commercial agreement under which distributors sell products of a given class at no less than a minimum price set by the manufacturer Fair.
4. Access to medication & healthcare Learning objectives: - to identify the why many people cannot access medication - to understand how NGOs and the UN.
Managing Procurement and Logistics of HIV/AIDS Drugs and Related Supplies By Yvonne Nkrumah Legal Counsel, Ghana Food and Drugs Board.
The emerging powers and the majority of the world Geographical Superpowers.
Tensions between Brazil and the United States
Access to Medications: An introduction Braveen Ragunanthan Keanan McGonigle Slides prepared by: Alison Case, Education and Advocacy Fellow Katrina Ciraldo,
South Africa’s Acceptance of the Protocol Amending the TRIPS Agreement Xolelwa Mlumbi- Peter DDG: ITED 24 November 2015.
Access to medicines Elizabeth Holzer, Legal Policy Advisor A global and local - legal and health systems issues.
The Role of Patents, Universities, and Non-Profits in the Promotion of Health Care Access Nina Gandhi.
GMP- A Regulatory Perspective. Regulatory Perspective in entering Global Pharma Markets.
Issues related to poor IP protection in EMs: Pharmaceutical Example Rob May Commercial Director, Janssen, EMEA Emerging Markets.
Good or Bad For America?. Whom does it benefit: Consumer or Business What impact is it having? Helpful or harmful? – For Businesses? Workers? Consumers?
The Global Drug Gap: Access Inequities and Policy Implications Michael R. Reich Harvard School of Public Health International Conference on Pharmacoepidemiology.
CAFTA: Boon to Innovation, or Obstacle for Women? Ellen R. Shaffer PhD MPH, Joe Brenner MA Center for Policy Analysis on Trade and Health (CPATH)
Introduction to Business © Thomson South-Western ChapterChapter Economic Decisions and Systems Economic Systems and Monopolies Supply and.
Access to medicines challenges in Europe: What is wrong and the way forward Presented by: Rohit Malpani Director of Policy & Analysis, Access Campaign.
TRADE NEGOTIATION ON PHARMACETICALS PRESENTED BY CHOGO,MALESO (092SIS10).
Human Rights and Access to Medicines Sean Flynn AU, Washington College of Law Abuja, Nigeria, November 2008.
The Benefits of Getting a License Agreement for Your Business
Difference to Generics What can they do for us in the future
Intellectual Property, Free Trade Agreements and sustainable Development Hanan Sboul Secretary General/ The Jordanian Association of Pharmaceutical Manufacturers.
IP, Invention Disclosures and Commercialization
IP-INITIAL® द्वारा प्रस्तुत IP-INITIAL®
Topic and Country Assignments
Social Pharmacy and Pharmacoeconomics.
Intellectual Property Protection and Access to Medicines
The Cost of Prescriptions
Patent law update.
Obligation to contribute to R&D costs Use of pharmaceutical inventions without authorization of patent owners James Love. CPTech 16 April 2004 Twelfth.
Acceptance of the Protocol Amending the TRIPS Agreement
Treat the world: Working united across diseases for quality and affordable treatment for all – AIDS 2018 TRIPS Flexibilities 0.2 Across Diseases Ellen.
INTELLECTUAL PROPERTY RIGHTS
Drug Pricing, Innovation, and the Cycle of Greed
Essential Question 6 What factors affect the level of competition in various U.S. industries?
Pharmaceuticals Industry
Presentation transcript:

Topic and Country Assignments Global Classrooms Topic and Country Assignments

Our Countries are… Togo Azerbaijan Congo Lebanon El Salvador Source: http://www.google.es/imgres?imgurl=http://geology.com/world/world-map.gif&imgrefurl=http://geology.com/world/world-map.shtml&h=715&w=1200&sz=98&tbnid=WyeCmd4K74fpMM:&tbnh=90&tbnw=151&zoom=1&usg=__hKLt0UL3_I_m9lGzOEBIP_MoqIk=&docid=19EM_yJbKFXQIM&sa=X&ei=f1RxUvr7IMvH7AbK-4GADQ&ved=0CDcQ9QEwAQ

Where are they? Source: http://www.google.es/imgres?imgurl=http://geology.com/world/world-map.gif&imgrefurl=http://geology.com/world/world-map.shtml&h=715&w=1200&sz=98&tbnid=WyeCmd4K74fpMM:&tbnh=90&tbnw=151&zoom=1&usg=__hKLt0UL3_I_m9lGzOEBIP_MoqIk=&docid=19EM_yJbKFXQIM&sa=X&ei=f1RxUvr7IMvH7AbK-4GADQ&ved=0CDcQ9QEwAQ

Africa: Togo and Congo

Central America: El Salvador

The Middle East: Lebanon and Azerbaijan Source: http://www.infoplease.com/atlas/middleeast.html

The Groups are… Togo: María, Lorena, Alberto Azerbaijan: Andrea, Wisal, Adrián Congo: Vivian, David, Jesus **Let me clarify which Congo and I will let you know via email Lebanon: Elisa, Adán, Irene El Salvador: Alvaro, Manuela, Christian, Patricia

Our Conference Topic Is… GENERIC DRUGS UN Committee: World Health Organisation (WHO) Source: https://d3ojdig7p1k9j.cloudfront.net/wp-content/uploads/2013/08/generic-drugs.jpg

World Health Organisation Agency of the UN that provides leadership on global health matters Has 194 member nations Provides support and information on issues like food safety, HIV/AIDS, maternal health and scientific research Source: http://www.puntlandi.net/?p=430

Generic Drugs “A pharmaceutical product usually intended to be interchangeable with an innovative product that is manufactured without a license from the innovator company and marketed after the expiration date of the patent or other exclusive rights.”

Patents “A title granted by public authorities that confers a temporary monopoly for the exploitation of an invention on the person who registers it, furnishes a sufficiently clear and full description of it and claims this monopoly.” Forbids others from using the invention without the inventors’ permission Drug patents are usually in effect for 17-20 years After this period, other companies can produce and sell the drug without permission: AKA generic drugs Same chemical formula as the expensive major brand but at a much cheaper price

How are Generic Drugs Made and Why are they so Cheap? Major pharmaceutical companies put a lot of money into research and development of the drug and therefore charge a lot of money Generic drug companies have the chemical formula already available to them (no R&D) and do not have to worry about the expensive and time-consuming regulatory testing. Thus they do not need to charge as much money to make money.

Why do we care? Generic drugs are cheaper and therefore allow impoverished people to access drugs 8 million people in low and middle-income countries currently receive drugs for HIV/AIDS which would not be possible without generic drugs

But then what is the problem? Impoverished people need cheap generic drugs, but major pharmaceutical companies need to make money in order to research and develop drugs. If they can’t make money  No drugs No drugs  No treatment

The Road to Becoming a Drug A need is determined Research is done to find the best chemical formula (usually on the cell or protein level) The drug is put through a series of regulatory tests assigned by the government for the safety of people Cells  Animals  Human Trials (Clinical Trials) If the drug passes all the tests it can then be patented The drug can then be sold to consumers

On the Political Level In 1994 the World Trade Organization protected big pharmaceutical companies via the TRIPS (Trade- Related Aspects of Intellectual Property Rights) Agreement However, a country could override the patent protection by issuing a “compulsory license” when they were in the midst of an epidemic

On the Political Level However, many countries began to abuse their compulsory licenses Ex. Thailand in 2006 was not able to negotiate a cheap enough price with Pharm companies and issued a compulsory license for cancer drugs Diseases like Cancer, Diabetes, and Heart Disease are known as non-communicable diseases as they are not passed from person to person. Again, Big Pharma companies need the money to do research and development of new drugs

Current Situation Generic Drug production is increasing Research and Development costs are increasing Big Pharma companies have introduced tiered pricing based on their clients income level Helps low income countries but not middle income countries Main problem surrounds HIV/AIDS drugs, whose patents are quickly expiring and which are expertly produced at low prices in countries like India

Further Problems Many second line drugs (newer versions of the drug with less resistance or toxicity) are still under patents and impoverished countries must rely on older, less effective methods While countries like the United States have put forth a lot of effort into making sure poor countries have access to HIV/AIDS drugs, they have also increased patent protection on non-communicable disease drugs. They argue that cancer and diabetes are less of an emergency than HIV/AIDS, malaria, and TB.

Source Global Classrooms. “World Health Organization (WHO), Topic: Generic Drugs.” Global Classrooms 2013. Print.

So things to keep in mind: Big pharma expenses versus profits Need for cheap drugs versus need for expensive drugs that fund future research Tiered pricing pros and cons

Country Presentations NEXT THURSDAY 10 MINUTES (and no more!) Citations! I WILL NOT ACCEPT LATE PRESENTATIONS! Everyone must speak

Country Presentations What you should include Government (Government system, Head of State, Languages) Economy (GDP, Economic System, Development classification, import/exports, natural resources) People (Religions, growth rate, standard of living) Military UN Relations (Has the UN had to intervene in a country conflict?) Relations with WHO and what you think is the country’s position on the generic drugs debate

Research Aids WHO Website UN Website Allcountries.eu Council on Foreign Relations (cfr.org)